187 related articles for article (PubMed ID: 19959962)
1. Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance.
Ina S; Hirono S; Noda T; Yamaue H
Pancreas; 2010 May; 39(4):473-85. PubMed ID: 19959962
[TBL] [Abstract][Full Text] [Related]
2. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.
Akada M; Crnogorac-Jurcevic T; Lattimore S; Mahon P; Lopes R; Sunamura M; Matsuno S; Lemoine NR
Clin Cancer Res; 2005 Apr; 11(8):3094-101. PubMed ID: 15837765
[TBL] [Abstract][Full Text] [Related]
3. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
4. ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7.
Meng Y; Bian L; Zhang M; Zhou P; Zhang S; Ying Y; Yang S; Liu Y; Yao Y; Li D
Int J Biol Sci; 2024; 20(4):1180-1193. PubMed ID: 38385083
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.
Funamizu N; Lacy CR; Kamada M; Yanaga K; Manome Y
Int J Oncol; 2019 Mar; 54(3):991-1000. PubMed ID: 30628651
[TBL] [Abstract][Full Text] [Related]
6. DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer.
Chen Y; Kang M; Lu W; Guo Q; Zhang B; Xie Q; Wu Y
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1463-74. PubMed ID: 22526154
[TBL] [Abstract][Full Text] [Related]
7. Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis.
Nakai Y; Otsuka M; Hoshida Y; Tada M; Komatsu Y; Kawabe T; Omata M
Oncol Rep; 2005 Nov; 14(5):1263-7. PubMed ID: 16211294
[TBL] [Abstract][Full Text] [Related]
8. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH
Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681
[TBL] [Abstract][Full Text] [Related]
9. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Samulitis BK; Pond KW; Pond E; Cress AE; Patel H; Wisner L; Patel C; Dorr RT; Landowski TH
Cancer Biol Ther; 2015; 16(1):43-51. PubMed ID: 25485960
[TBL] [Abstract][Full Text] [Related]
13. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
Arumugam T; Ramachandran V; Fournier KF; Wang H; Marquis L; Abbruzzese JL; Gallick GE; Logsdon CD; McConkey DJ; Choi W
Cancer Res; 2009 Jul; 69(14):5820-8. PubMed ID: 19584296
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.
Huanwen W; Zhiyong L; Xiaohua S; Xinyu R; Kai W; Tonghua L
Mol Cancer; 2009 Dec; 8():125. PubMed ID: 20021699
[TBL] [Abstract][Full Text] [Related]
15. Mechanism Comparison of Gemcitabine and Dasatinib-Resistant Pancreatic Cancer by Integrating mRNA and miRNA Expression Profiles.
Chen Z; Zhao L; Shi K; Chen B
Clin Lab; 2018 May; 64(5):749-757. PubMed ID: 29739052
[TBL] [Abstract][Full Text] [Related]
16. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
[TBL] [Abstract][Full Text] [Related]
17. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Niess H; Camaj P; Renner A; Ischenko I; Zhao Y; Krebs S; Mysliwietz J; Jäckel C; Nelson PJ; Blum H; Jauch KW; Ellwart JW; Bruns CJ
Target Oncol; 2015 Jun; 10(2):215-27. PubMed ID: 24950733
[TBL] [Abstract][Full Text] [Related]
18. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
[TBL] [Abstract][Full Text] [Related]
19. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
